Navigation Links
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Date:10/2/2007

sed on cancer research.

"SDI is focused on the oncology segment of life science research and is committed to creating industry leading solutions for oncology research," Mr. Knight added. "This initial offering is a powerful step in that direction. As we expand this catalog, it will become the premier site for new and important antibody reagents for cancer research."

About Strategic Diagnostics, Inc.

Strategic Diagnostics Inc. develops, manufactures and markets biotechnology-based detection solutions to a diverse customer base, across multiple industrial and human health markets. By applying its core competency of creating custom antibodies to assay development, the Company produces unique, sophisticated diagnostic testing and reagent systems that are responsive to customer diagnostic and information needs. Customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in the pharmacogenomics market.

This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking
'/>"/>

SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
2. New Advances in Gastric Diagnostics: Smaller is Better
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
8. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
9. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
10. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
11. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Belgium, December 16 , ... Program With Microplasmin Recruits a Total of ... ThromboGenics NV (Euronext Brussels: ... and development of innovative treatments for eye,disease, ... it has completed,the enrolment of the second ...
(Date:12/15/2009)... Dec. 15 Warner Chilcott plc (Nasdaq: ... Warner Chilcott Corporation (the "Company") has commenced a ... to the conditions set forth in the Company,s ... December 15, 2009 (the "Offer to Purchase"), for ... subordinated notes due 2015 (the "Notes"). ,, The ...
(Date:12/15/2009)... Cellular Dynamics International ... iCell(TM) Cardiomyocytes for use in testing of new ... human heart cells are designed to aid drug ... efficacy and toxicity screens, weeding out ineffective and ... process before significant time and resources have been ...
Breaking Medicine Technology:ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 2Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 3Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 4Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 5Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015 6Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4Genova files patent for new prostate cancer treatment 56395 1Genova files patent for new prostate cancer treatment 56395 2Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 1Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 2Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 3Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 4Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 5Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 6Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 7Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 8Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 9Reportlinker Adds Small Molecule Kinase Inhibitors Report 13902 10Organic weed control for dandelions 9824 1Organic weed control for dandelions 9824 2
... June 13 , NicOx S.A. (Euronext Paris: ... pressure data from the 301 phase 3 study, ... in,terms of the mean change from baseline in ... for 3 out of 4 comparisons). Commonly used,Non-Steroidal ...
... June 12 XTENT, Inc.,(Nasdaq: XTNT ) ... the designated European Notified Body for CE Mark ... Notified Body confirmed that recently,presented six-month follow up ... by the Drug Agency, which reviews the drug ...
Other Medicine Technology:NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 2NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 3NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR 4XTENT Announces European Regulatory Update 2XTENT Announces European Regulatory Update 3
(Date:12/15/2009)... developed a new electrophoretic method for detecting MIRCERA ... The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity ... characteristics of SDS-PAGE for detecting other EPOs. ... from the World Anti-Doping Agency (WADA), appear in ... Analysis published by Wiley-Blackwell. , MIRCERA (methoxy ...
(Date:12/15/2009)... -- The failure of the U.S. Senate to ... much less the more effective direct bulk purchasing ... of how big industry controls the health reform ... amendment by Senator Dorgan (D-ND) was a relatively ... to allow Medicare to directly negotiate discounts with ...
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected ... Care Act that would have helped make prescription ... and legal importation of lower priced drugs from ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ... bring down the skyrocketing costs of prescription drugs. ...
(Date:12/15/2009)... Watchdog Calls For Preserving State Authority, Ban on ... ,, WASHINGTON, Dec. 15 Consumer Watchdog ... for those over 55 and the public option ... the group said that the Senate must still ... bill to prevent ceding the entire health care ...
(Date:12/15/2009)... NAPA, Calif., Dec. 15 Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences ... healthy aging, today announced that shareholders had approved all three resolutions that the Company had ... were as follows: , , Description of ... Votes ... For ...
Breaking Medicine News(10 mins):Health News:Researchers discover novel method for detecting MIRCERA 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 2Health News:Senetek PLC Announces 2009 Annual General Meeting Voting Results 3
... wore one. So did Winston Churchill and Ernest Hemingway. We ... in Ecuador. The elegant// headwear woven from palm fibres, considered ... a slow comeback., ,Custom-woven Panama hats are in worldwide ... refining ones imported from Ecuador., ,"These days when people ...
... generosity, Canada based Kevin Gosling donated a part of his liver ... an incurable liver disease //. He further stated that he had ... about putting his own life at risk, adding that he would ... donation had on one of his family friends is said to ...
... in the past year, raising fears of a surge of ... AIDS cases. // It is estimated that nearly 350,000 ... have crossed one million. ,What Russia needs to do ... medical services for the infected people. It is said that ...
... clenbuterol, originally intended for treatment of asthmatics can now help ... last step for many heart failure patients is a heart ... patients have to survive on heart pumps, reported the online ... found that clenbuterol results in significant improvement in the cardiac ...
... identify, highlight and deliver genes to mice tumor cells have ... M. D. Anderson Cancer Center. This new development, reported in ... it could lead to novel treatment strategies for combating cancer. ... cancer cells and makes it more accessible to treatment, it ...
... popularize their calorie-dense, low-nutrient foods have a negative impact ... Public Health (HSPH) and Children's Hospital Boston studied the ... results appear in the Archives of Pediatric and Adolescent ... viewing is a risk factor for overweight as kids ...
Other Medicine News:Health News:Panama hat making a slow comeback 2Health News:46-Year-Old Canada Man Donates A Part Of His Liver To A Complete Stranger 2Health News:Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced 2
... laser is mounted on Haag Streit slit-lamp. ... 0.2 and 2.0 mJ. The spot size ... microns. Knobs for laser energy and aiming ... laser head. The laser system complies with ...
... laser system provides two lasers in the ... photodisruptor for posterior capsulotomy and iridotomy. The ... pulsed 532 nm light. The photodisruptor laser ... appropriate laser can be easily selected and ...
... The Selecta II Glaucoma Laser System features ... patients with open-angle glaucoma. It selectively targets ... intraocular pressure. The Selecta II is equipped ... high-energy beam of light, which induces the ...
Thin and smooth jaws, designed to enter trough 3 mm incision, cross action....
Medicine Products: